Evidence map›Paper›PMID 30114402›Full record

ArticleNeuropharmacology2018

Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS.

Douglas J Hermes, Changqing Xu, Justin L Poklis, Micah J Niphakis, Benjamin F Cravatt, Ken Mackie, Aron H Lichtman, Bogna M Ignatowska-Jankowska, Sylvia Fitting

Open access · hybridAbstract read
In one paragraph

Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The impact of cannabinoids on inflammasome signaling in HIV-1 infection.NeuroImmune pharmacology and therapeutics · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Douglas J HermesDepartment of Psychology & Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: aerime@live.unc.edu.
Changqing XuDepartment of Psychology & Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Justin L PoklisDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Micah J NiphakisDepartment of Chemical Physiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Benjamin F CravattDepartment of Chemical Physiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Ken MackieDepartment of Psychological & Brain Science, Indiana University Bloomington, Bloomington, IN 47405, USA.
Aron H LichtmanDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Bogna M Ignatowska-JankowskaOkinawa Institute of Science and Technology, Neuronal Rhythms in Movement Unit, Okinawa 904-0495, Japan.
Sylvia FittingDepartment of Psychology & Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: sfitting@email.unc.edu.
University of North Carolina at Chapel Hill · USScripps Research Institute · USVirginia Commonwealth University · USIndiana University Bloomington · USOkinawa Institute of Science and Technology Graduate University · JP

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Matthew Sean Halquist · 2014 to 2026
$13.8M
Training on Research in Drug AbuseT32DA007244 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Regina M Carelli · 1990 to 2026
$7.6M
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6M
Endocannabinoid-mediated neuroprotection in models of neuroAIDS in vivoR01DA045596 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2018 to 2022
$1.9M
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (RO)R01DA032933 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, LICHTMAN, ARON H · 2012 to 2014
$1.5M
Cannabinoid Modulation of Cell FunctionK05DA021696 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI MACKIE, KENNETH · 2007 to 2017
$1.3M
Opiate drug abuse & HIV-induced excitotoxicity in striatal neuronsR00DA033878 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2015 to 2017
$745k
Investigation of endocannabinoid-mediated neuroprotection in models of neuroAIDSR21DA041903 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2016 to 2017
$407k
Targeting FAAH to treat Alzheimers diseaseR21AG042745 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI LICHTMAN, ARON H · 2012 to 2013
$401k
NIAID NIH HHS P30 AI050410NIA NIH HHS R21 AG042745NIDA NIH HHS K05 DA021696NIDA NIH HHS P30 DA033934NIDA NIH HHS R00 DA033878NIDA NIH HHS R01 DA032933NIDA NIH HHS R01 DA039942NIDA NIH HHS R01 DA045596NIDA NIH HHS R21 DA041903NIDA NIH HHS T32 DA007244
6 · The paper itself

Abstract

The HIV-1 transactivator of transcription (Tat) is a neurotoxin involved in the pathogenesis of HIV-1 associated neurocognitive disorders (HAND). The neurotoxic effects of Tat are mediated directly via AMPA/NMDA receptor activity and indirectly through neuroinflammatory signaling in glia. Emerging strategies in the development of neuroprotective agents involve the modulation of the endocannabinoid system. A major endocannabinoid, anandamide (N-arachidonoylethanolamine, AEA), is metabolized by fatty acid amide hydrolase (FAAH). Here we demonstrate using a murine prefrontal cortex primary culture model that the inhibition of FAAH, using PF3845, attenuates Tat-mediated increases in intracellular calcium, neuronal death, and dendritic degeneration via cannabinoid receptors (CB

Indexed as

Acquired Immunodeficiency SyndromeAmidohydrolasesAnimalsArachidonic AcidsCalciumCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsCaspase 3Cell DeathEndocannabinoidsFatty Acid Amide HydrolasesHIV-1IndolesMiceNerve DegenerationNeuroprotective AgentsAmidohydrolasesanandamideArachidonic AcidsCalciumCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsCaspase 3EndocannabinoidsFatty Acid Amide HydrolasesIndolesiodopravadolineNeuroprotective AgentsPF 3845PiperidinesPolyunsaturated AlkamidesPyridinesRimonabanttat Gene Products, Human Immunodeficiency VirusAnandamideCannabinoidsHIV-1 TatNeurodegenerationNeuroprotection

Identifiers

PMID30114402
PMCPMC6296377
OpenAlexW2887191509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.